Found: 2

Select item for more details and to access through your institution.

  • The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases.

    Published in:
    UHOD: International Journal of Hematology & Oncology / Uluslararasi Hematoloji Onkoloji Dergisi, 2016, v. 26, n. 3, p. 153, doi. 10.4999/uhod.161338
    By:
    • AKTIMUR, Sude H.;
    • MALKAN, Umit Y.;
    • EYUPOGLU, Damla N.;
    • HAZNEDAROGLU, Ibrahim C.;
    • KELKITLI, Engin;
    • ATAY, Hilmi M.;
    • GUNES, Gursel;
    • ETGUL, Sezgin;
    • ASLAN, Tuncay;
    • GOKER, Hakan;
    • SAYINALP, Nilgun;
    • AKSU, Salih;
    • OZCEBE, Osman I.;
    • BUYUKASIK, Yahya;
    • TURGUT, Mehmet
    Publication type:
    Article

  • Generic Imatinib Mesylate is as Effective as Original Glivec in the Clinical Management of CML.

    Published in:
    UHOD: International Journal of Hematology & Oncology / Uluslararasi Hematoloji Onkoloji Dergisi, 2015, v. 25, n. 4, p. 215, doi. 10.4999/uhod.1111
    By:
    • MALKAN, Umit Y.;
    • AKSU, Salih;
    • AKTIMUR, Sude H.;
    • ATAY, Hilmi;
    • BEKTAS, Ozlen;
    • BUYUKASIK, Yahya;
    • DEMIROGLU, Haluk;
    • ELIACIK, Eylem;
    • ESME, Mert;
    • HACIHANEFIOGLU, Abdullah;
    • GUNES, Gursel;
    • GÖKER, Hakan;
    • KARAKUS, Sema;
    • KILICKAP, Saadettin;
    • KOCA, Ebru;
    • OZCEBE, Osman I.;
    • SAYINALP, Nilgun;
    • TARKUN, Pınar;
    • TURGUT, Mehmet;
    • HAZNEDAROGLU, Ibrahim C.
    Publication type:
    Article